http://www.fpnotebook.com/
AzathioprineAka: Imuran
- Indications
- Renal homograft maintenance
- Myasthenia Gravis
- Systemic Lupus Erythematosus (Lupus Nephritis)
- Acute Glomerulonephritis
- Pharmacology
- Imidazolyl derivative of mercaptopurine
- Metabolized to mercaptopurine as active ingredient
- Structural Analogue Chemotherapy (purine)
- Adverse effects (similar to mercaptopurine)
- Bone Marrow suppression
- Leukopenia
- Anemia
- Thrombocytopenia
- Skin rash
- Drug Fever
- Nausea, Vomiting or Diarrhea
- Hepatic dysfunction
- Monitoring
- Complete Blood Count
- Liver Function Tests
|
|---|
| Definition (MSH) | An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) |
| Definition (CSP) | immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis; possible carcinogen. |
| Definition (NCI) | A purine analogue with cytotoxic and immunosuppressive activity. Azathioprine is a prodrug that is converted by hepatic xanthine oxidase to its active metabolite 6-mercaptopurine (6-MP). 6-MP is further metabolized by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) into 6-thioguanosine-5'-phosphate (6-thio-GMP) and 6-thioinosine monophosphate (6-thio-IMP), both inhibit nucleotide conversions and de novo purine synthesis. This leads to inhibition of DNA, RNA, and protein synthesis. As a result, cell proliferation may be inhibited, particularly in lymphocytes and leukocytes. |
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | AZA, Azathioprine, AZATHIOPRINE PREPARATION, Azothioprine, AZTP |
| Spanish | azatioprina |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree
